286 related articles for article (PubMed ID: 26705740)
1. T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells.
D'Aloia MM; Caratelli S; Palumbo C; Battella S; Arriga R; Lauro D; Palmieri G; Sconocchia G; Alimandi M
Cytotherapy; 2016 Feb; 18(2):278-90. PubMed ID: 26705740
[TBL] [Abstract][Full Text] [Related]
2. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma.
Darcy PK; Kershaw MH; Trapani JA; Smyth MJ
Eur J Immunol; 1998 May; 28(5):1663-72. PubMed ID: 9603473
[TBL] [Abstract][Full Text] [Related]
3. In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer.
Clémenceau B; Valsesia-Wittmann S; Jallas AC; Vivien R; Rousseau R; Marabelle A; Caux C; Vié H
J Immunol Res; 2015; 2015():482089. PubMed ID: 26665156
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
Hombach A; Hombach AA; Abken H
Gene Ther; 2010 Oct; 17(10):1206-13. PubMed ID: 20555360
[TBL] [Abstract][Full Text] [Related]
5. Fas-ligand-mediated lysis of erbB-2-expressing tumour cells by redirected cytotoxic T lymphocytes.
Haynes NM; Smyth MJ; Kershaw MH; Trapani JA; Darcy PK
Cancer Immunol Immunother; 1999 Jan; 47(5):278-86. PubMed ID: 10022472
[TBL] [Abstract][Full Text] [Related]
6. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
7. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
8. Thy-1 signaling in the context of costimulation provided by dendritic cells provides signal 1 for T cell proliferation and cytotoxic effector molecule expression, but fails to trigger delivery of the lethal hit.
Haeryfar SM; Al-Alwan MM; Mader JS; Rowden G; West KA; Hoskin DW
J Immunol; 2003 Jul; 171(1):69-77. PubMed ID: 12816984
[TBL] [Abstract][Full Text] [Related]
9. Gene-modified human α/β-T cells expressing a chimeric CD16-CD3ζ receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy.
Ochi F; Fujiwara H; Tanimoto K; Asai H; Miyazaki Y; Okamoto S; Mineno J; Kuzushima K; Shiku H; Barrett J; Ishii E; Yasukawa M
Cancer Immunol Res; 2014 Mar; 2(3):249-62. PubMed ID: 24778321
[TBL] [Abstract][Full Text] [Related]
10. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
[TBL] [Abstract][Full Text] [Related]
11. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
12. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing.
Kudo K; Imai C; Lorenzini P; Kamiya T; Kono K; Davidoff AM; Chng WJ; Campana D
Cancer Res; 2014 Jan; 74(1):93-103. PubMed ID: 24197131
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy.
Jonnalagadda M; Mardiros A; Urak R; Wang X; Hoffman LJ; Bernanke A; Chang WC; Bretzlaff W; Starr R; Priceman S; Ostberg JR; Forman SJ; Brown CE
Mol Ther; 2015 Apr; 23(4):757-68. PubMed ID: 25366031
[TBL] [Abstract][Full Text] [Related]
14. High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
Rataj F; Jacobi SJ; Stoiber S; Asang F; Ogonek J; Tokarew N; Cadilha BL; van Puijenbroek E; Heise C; Duewell P; Endres S; Klein C; Kobold S
Br J Cancer; 2019 Jan; 120(1):79-87. PubMed ID: 30429531
[TBL] [Abstract][Full Text] [Related]
15. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
16. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
Mardiros A; Dos Santos C; McDonald T; Brown CE; Wang X; Budde LE; Hoffman L; Aguilar B; Chang WC; Bretzlaff W; Chang B; Jonnalagadda M; Starr R; Ostberg JR; Jensen MC; Bhatia R; Forman SJ
Blood; 2013 Oct; 122(18):3138-48. PubMed ID: 24030378
[TBL] [Abstract][Full Text] [Related]
17. Contribution of dendritic cells' FcgammaRI and FcgammaRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies.
Signorino E; Brusa D; Granata R; Malavasi F; Ferrone S; Matera L
Cancer Biol Ther; 2007 Dec; 6(12):1932-7. PubMed ID: 18087220
[TBL] [Abstract][Full Text] [Related]
18. FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance.
Caratelli S; Sconocchia T; Arriga R; Coppola A; Lanzilli G; Lauro D; Venditti A; Del Principe MI; Buccisano F; Maurillo L; Ferrone S; Sconocchia G
Front Immunol; 2017; 8():457. PubMed ID: 28496440
[TBL] [Abstract][Full Text] [Related]
19. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.
Yun CO; Nolan KF; Beecham EJ; Reisfeld RA; Junghans RP
Neoplasia; 2000; 2(5):449-59. PubMed ID: 11191112
[TBL] [Abstract][Full Text] [Related]
20. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor.
Reinhold U; Liu L; Lüdtke-Handjery HC; Heuser C; Hombach A; Wang X; Tilgen W; Ferrone S; Abken H
J Invest Dermatol; 1999 May; 112(5):744-50. PubMed ID: 10233766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]